Get the Stockscreener App
7.70
3.08%
0.23
After Hours:
7.70
Tango Therapeutics Inc stock is traded at $7.70, with a volume of 1.00M.
It is up +3.08% in the last 24 hours and down -34.91% over the past month.
Tango Therapeutics Inc is a biotechnology company. It is dedicated towards discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. It is engaged in the business of discovering and developing precision oncology therapies. Its program TNG908, is an MTA-cooperative inhibitor of PRMT5 designed to work selectively in cancer cells with an MTAP deletion. Its pipeline further consists of discovery programs such as, TNG462, TNG348, TNG260 and others for multiple cancer types with limited treatment options.
See More
Previous Close:
$7.47
Open:
$7.43
24h Volume:
1.00M
Relative Volume:
1.11
Market Cap:
$807.87M
Revenue:
$42.51M
Net Income/Loss:
$-116.49M
P/E Ratio:
-6.3636
EPS:
-1.21
Net Cash Flow:
$-120.82M
1W Performance:
+0.13%
1M Performance:
-34.91%
6M Performance:
-3.02%
1Y Performance:
-31.62%
1-Day Range:
$7.42
$7.78
1-Week Range:
$7.20
$7.95
52-Week Range:
$5.15
$13.03
Tango Therapeutics Inc Stock (TNGX) Company Profile
Name
Tango Therapeutics Inc
Sector
Industry
Phone
(857) 320-4900
Address
201 BROOKLINE AVENUE, BOSTON
Tango Therapeutics Inc Stock (TNGX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-08-23 | Initiated | B. Riley Securities | Buy |
| Oct-20-22 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Sep-20-21 | Initiated | SVB Leerink | Outperform |
Tango Therapeutics Inc Stock (TNGX) Latest News
Post-Trade Analysis: Tango Therapeutics Inc (TNGX) Climbs 1.49, Closing at 7.47 - The Dwinnex
What technical indicators reveal about TNGX stock - US Post News
Tango Therapeutics, Inc. (NASDAQ:TNGX) Shares Sold by Ensign Peak Advisors Inc - MarketBeat
Pancreatic Cancer Market to Reach New Heights in Growth by 2034, DelveInsight Predicts | Dragonfly Therapeutics, Keymed B, Tango Therapeutics, Atara Biotherapeutics, Keymed Biosciences Co. Ltd - Barchart
Tango Therapeutics Inc [TNGX] stock for 709,756 USD was sold by Third Rock Ventures IV, L.P. - Knox Daily
Tango Therapeutics, Inc. (NASDAQ:TNGX) Receives Consensus Rating of "Buy" from Analysts - MarketBeat
Take off with Tango Therapeutics Inc (TNGX): Get ready for trading - SETE News
Tango Therapeutics Inc’s latest rating changes from various analysts - Knox Daily
Tango Therapeutics (NASDAQ:TNGX) Trading Down 3% - MarketBeat
Gaining Ground: Tango Therapeutics Inc (TNGX) Closes Lower at 8.30, Down -1.31 - The Dwinnex
Is Tango Therapeutics Inc (TNGX) a good investment opportunity? - US Post News
Head to Head Contrast: Panbela Therapeutics (NASDAQ:PBLA) & Tango Therapeutics (NASDAQ:TNGX) - Defense World
Tango Therapeutics, Inc. (NASDAQ:TNGX) Stock Holdings Lifted by Bank of New York Mellon Corp - Defense World
Insider Selling: Third Rock Ventures IV, L.P., Tango Therapeutics Inc [TNGX] 10% Owner divested 67,400 shares - Knox Daily
Rock Ventures Iv L.P. Third Sells 67,400 Shares of Tango Therapeutics, Inc. (NASDAQ:TNGX) Stock - Defense World
Tango Therapeutics (NASDAQ:TNGX) Trading Up 3% - MarketBeat
Investors in cash trouble should check out Tango Therapeutics Inc (TNGX) - SETE News
Tango Therapeutics (NASDAQ:TNGX) Stock Price Up 3% - Defense World
Piper Sandler maintains Overweight rating on Tango Therapeutics shares - Investing.com
Third Rock Ventures sells shares in Tango Therapeutics worth over $700k - Investing.com India
Tango Therapeutics, Inc. (NASDAQ:TNGX) Major Shareholder Rock Ventures Iv L.P. Third Sells 67,400 Shares - MarketBeat
Third Rock Ventures sells shares in Tango Therapeutics worth over $700k - Investing.com
Tango Therapeutics Inc (TNGX) Stock: A Year of Stock Market Ups and Downs - The InvestChronicle
Piper Sandler maintains Overweight rating on Tango Therapeutics shares - Investing.com India
Piper Sandler maintains Overweight rating on Tango Therapeutics shares By Investing.com - Investing.com UK
Ratios Uncovered: Breaking Down Tango Therapeutics Inc (TNGX)’s Trailing Twelve Months Metrics - The Dwinnex
Principal Financial Group Inc. Takes Position in Tango Therapeutics, Inc. (NASDAQ:TNGX) - Defense World
Tango Therapeutics Inc [TNGX] Investment Appeal on the Rise - Knox Daily
Tango Therapeutics (NASDAQ:TNGX) Shares Down 12.4% - MarketBeat
Tango Therapeutics Inc (TNGX) stock: A year of ups and downs - US Post News
Stock Surge: Tango Therapeutics Inc (TNGX) Closes at 10.00, Marking a 3.20 Increase/Decrease - The Dwinnex
Tango Therapeutics Inc’s (TNGX) Stock Is Harder To Predict Than You Think - Stocks Register
Tango Therapeutics (NASDAQ:TNGX) Trading Up 8.8% - MarketBeat
A company insider recently sold 75,000 shares of Tango Therapeutics Inc [TNGX]. Should You also Consider to Sale? - Knox Daily
This trade activity should not be overlooked: Tango Therapeutics Inc (TNGX) - SETE News
Tango Therapeutics’ (TNGX) “Buy” Rating Reaffirmed at HC Wainwright - Defense World
Wainwright holds target, buy rating on Tango Therapeutics shares - Investing.com
Tango Therapeutics: Amgen Missteps Devalue PRMT5 Candidates Ahead Of Critical Data (TNGX) - Seeking Alpha
Tango Therapeutics (NASDAQ:TNGX) Rating Reiterated by HC Wainwright - MarketBeat
Analyst Scoreboard: 4 Ratings For Tango Therapeutics - Benzinga
Third Rock Ventures sells $867k of Tango Therapeutics stock - Investing.com India
Insider Selling: Tango Therapeutics, Inc. (NASDAQ:TNGX) Major Shareholder Sells 75,000 Shares of Stock - MarketBeat
Third Rock Ventures sells $867k of Tango Therapeutics stock - Investing.com
Third Rock Ventures sells $867k of Tango Therapeutics stock By Investing.com - Investing.com UK
Tango Therapeutics Inc Inc. (TNGX) Price Performance: The Role of Share Buybacks and Stock Splits - The InvestChronicle
Market Highlights: Tango Therapeutics Inc (TNGX) Ends on a Low Note at 10.89 - The Dwinnex
Tango Therapeutics (NASDAQ:TNGX) Shares Gap Down to $10.89 - MarketBeat
Tango Therapeutics maintains stock target, Overweight rating on latest data By Investing.com - Investing.com Canada
Technical analysis of Tango Therapeutics Inc (TNGX) stock chart patterns - US Post News
Tango Therapeutics maintains stock target, Overweight rating on latest data - Investing.com
Tango Therapeutics Inc (TNGX) Becoming More Attractive for Investors - Knox Daily
Tango Therapeutics Inc Stock (TNGX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.05%
4.86%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):